Suchergebnisse - "Tumani, Hayrettin"

PubPharm (528)

1

Targeted proteomics upon Tofersen identifies candidate response markers for SOD1-linked amyotrophic lateral sclerosis

enthalten in: bioRxiv.org | 2024

von Steffke, C. | Baskar, K. | Wiesenfarth, M. | +34

2

Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy

enthalten in: Journal of autoimmunity | 2024

von Huth, A. | Ayoub, I. | Barateau, L. | +12

3

Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays

enthalten in: bioRxiv.org | 2024

von Fazeli, B. | Gómez de San José, N. | Jesse, S. | +6

4

Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

enthalten in: Journal of neurology, neurosurgery, and psychiatry | 2024

von Fissolo, N. | Benkert, P. | Sastre-Garriga, J. | +33

5

Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD

enthalten in: Annals of neurology | 2024

von Duchow, A. | Bellmann-Strobl, J. | Friede, T. | +95

6

Neurofilaments as biomarkers in neurological disorders - towards clinical application

enthalten in: Nature reviews. Neurology | 2024

von Khalil, M. | Teunissen, C. | Lehmann, S. | +20

7

Correction to : Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

enthalten in: Journal of neurology | 2024

von Kümpfel, T. | Giglhuber, K. | Aktas, O. | +122

ErratumFor: J Neurol. 2024 Jan;271(1):141-176. - PMID 37676297

8

Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories

enthalten in: Science translational medicine | 2024

von Gross, C. | Schulte-Mecklenbeck, A. | Steinberg, O. | +66

9

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study

enthalten in: Neurological research and practice | 2024

von Bayas, A. | Mansmann, U. | Ön, B. | +44

10

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

enthalten in: Neurological research and practice | 2024

von Bayas, A. | Mansmann, U. | Ön, B. | +34

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[53]